HiPEG™ IFN α-2a

PolyTherics has produced an improved version of IFN α-2a by engineering a histidine-tag at the N terminus of the protein. The precision chemistry of the Company’s HiPEG™ technology has been used to selectively conjugate PEG to the tag’s histidine-residues.

The activity of HiPEG™ IFN α-2a has been shown to be eight-fold higher than that of a marketed PEGylated IFN a in an in vitro assay.

The half-life HiPEG™ IFN α-2a has been shown to be comparable to that of a marketed PEGylated IFN a in a preclinical study.

The manufacture of HiPEG™ IFN α-2a has been transferred to a contract manufacturing organisation for scale-up and production for preclinical and clinical studies.

If you are interested in discussing licence terms to develop and/or commercialise
HiPEG™ IFN α-2a contact Business Development.